Multiple tumor marker elevation in androgen ablation-refractory prostate cancer with long-term response to metronomic chemotherapy: A case report

International Journal of Biological Markers

Volumn 25, Issue 4, 2010, Pages 243-247

  Massaccesi, Mariangela ^a   Forni, Franca ^b   Spagnuolo, Pasquale ^c   Macchia, Gabriella ^a   Mignogna, Samantha ^a   De Ninno, Maria ^a   Cellini, Numa ^b   Giardina, Bruno ^b   Carbone, Arnaldo ^a   Morganti, Alessio G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c General Hospital   (Italy)

Author keywords

CA 19 9; CEA; Chromogranin A; Metronomic therapy; Prostate cancer; PSA

Indexed keywords

BICALUTAMIDE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; ANDROGEN DEPRIVATION THERAPY; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; BONE BIOPSY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; COLON ADENOCARCINOMA; DRUG RESPONSE; DRUG TOLERABILITY; EVENING DOSAGE; HUMAN; HUMAN TISSUE; HYPOXIA; MALE; METRONOMIC CHEMOTHERAPY; MORNING DOSAGE; PROSTATE CANCER;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN A; COLONIC NEOPLASMS; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650852515     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2010.6109     Document Type: Article

References (22)

1. Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenetic window for various chemotherapeutic drugs. Cancer Res 2002; 62: 638-43. (Pubitemid 35424084)
2. Glode L, Barqawi A, Crighton F, Crawford E, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003; 98: 1643-8. (Pubitemid 37238620)
3. Lord R, Nair S, Schache A, et al. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 2007; 177: 2136-40.
4. Nicolini A, Mancini P, Ferrari P, et al. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed Pharmacother 2004; 58: 447-50.
5. Salazar OM, Sandhu T, da Motta NW, et al. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: A randomized phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys 2001; 50: 765-75.
6. Petrylak DP. Chemotherapy for androgen independent prostate cancer. Semin Urol Oncol 2002; 20: 31-5.
7. Berruti A, Mosca A, Tucci M, et al. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005; 12: 109-17.
8. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997; 30: 1-6.
9. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate 1998; 8: 18-22.
10. Hamano Y, Sugimoto H, Soubasakos MA, et al. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res 2004; 64: 1570-4.
11. Roberts DD, Isenberg JS, Ridnour LA, Wink DA. Nitric oxide and its gatekeeper thrombospondin-1 in tumor angiogenesis. Clin Cancer Res 2007; 13: 795-8.
12. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996; 74: 910-6.
13. Borre M, Nerstrøm B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000; 6: 1882-90.
14. Tsukushi S, Katagiri H, Kataoka T, Nishida Y, Ishiguro N. Serum tumor markers in skeletal metastasis. Jpn J Clin Oncol 2006; 36: 439-44.
15. Kato T, Hashimoto Y, Okada S, Tozawa K, Takahashi S, Kohri K. Carbohydrate antigen 19-9-positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine. Int J Urol 2007; 14: 1103-6.
16. Emmenegger U, Morton GC, Francia G, et al. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res 2006; 66: 1664-74.
17. Blagosklonny MV. Antiangiogenic therapy and tumor progression. Cancer Cell 2004; 5: 13-7.
18. Koike T, Kimura N, Miyazaki K, et al. Hypoxia induces 18. adhesion molecules on cancer cells - a missing link between Warburg effect and induction of selectin ligand carbohydrates. Proc Natl Acad Sci U S A 2004; 101: 8132-7.
19. Tei K, Kawakami-Kimura N, Taguchi O, et al. Roles of cell adhesion molecules in tumor angiogenesis induced by cotransplantation of cancer and endothelial cells to nude rats. Cancer Res 2002; 62: 6289-96.
20. Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 2004; 95: 377-84.
21. Kokkonen N, Ulibarri IF, Kauppila A, et al. Hypoxia upregulates carcinoembryonic antigen expression in cancer cells. Int J Cancer 2007; 121: 2443-50.
22. Wagener C, Ergün S. Angiogenic properties of the carcinoembryonic antigen-related cell adhesion molecule 1. Exp Cell Res 2000; 261: 19-24.